日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. FOLR1 (Mirvetuximab soravtansine Biosimilar) Recombinant Monoclonal Antibody

FOLR1 (Mirvetuximab soravtansine Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA008784MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    FOLR1重組單克隆抗體（Mirvetuximab soravtansine Biosimilar Antibody）是一種靶向葉酸受體1（FOLR1）的治療性抗體，其別名包括葉酸結(jié)合蛋白抗體、葉酸受體α抗體、FRα抗體、FOLR1_HUMAN抗體等，在科研文獻中也常被稱為MOv18抗體或卵巢腫瘤相關(guān)抗原抗體。該抗體以重組人FOLR1蛋白制備，具有高度靶向性，可特異性識別并結(jié)合人及食蟹猴的FOLR1分子，展現(xiàn)出嚴(yán)格的種屬反應(yīng)性。 Mirvetuximab soravtansine因其對FOLR1的高親和力而成為實體瘤治療的重要藥物。FOLR1在卵巢癌、非小細(xì)胞肺癌、乳腺癌等多種上皮來源腫瘤中高表達，尤其與卵巢癌的發(fā)生發(fā)展密切相關(guān)，因此該抗體研發(fā)的藥物被廣泛應(yīng)用于相關(guān)惡性腫瘤的靶向治療。臨床前及早期臨床試驗顯示，其通過抗體依賴的細(xì)胞毒性（ADCC）、補體依賴的細(xì)胞毒性（CDC）等機制發(fā)揮抗腫瘤作用，部分研究還探索了其與化療藥物、免疫檢查點抑制劑的聯(lián)合治療方案，旨在提高治療效果并降低脫靶毒性。 FOLR1抗體是腫瘤生物學(xué)研究的關(guān)鍵工具?；谄涿鞔_的種屬反應(yīng)性，研究者可利用人源腫瘤細(xì)胞系（如KB細(xì)胞）及食蟹猴動物模型，開展FOLR1表達調(diào)控、信號通路機制及腫瘤微環(huán)境相互作用等基礎(chǔ)研究。此外，該抗體還可用于腫瘤組織樣本的FOLR1表達檢測，為腫瘤分型、預(yù)后評估及患者篩選提供實驗依據(jù)，助力精準(zhǔn)醫(yī)療策略的開發(fā)。其多樣化的別名提示研究者在文獻檢索時需關(guān)注不同命名方式，以全面獲取相關(guān)研究進展。
  • Uniprot No.：
  • 基因名：
  • 別名：
    adult antibody; Adult folate binding protein antibody; Adult folate-binding protein antibody; FBP antibody; Folate Binding Protein antibody; Folate Receptor 1 Adult antibody; Folate receptor 1 antibody; Folate Receptor 1 Precursor antibody; Folate receptor adult antibody; Folate receptor alpha antibody; Folate receptor antibody; FOLR antibody; FOLR1 antibody; FOLR1_HUMAN antibody; FR alpha antibody; FR-alpha antibody; FRalpha antibody; KB cells FBP antibody; MOV18 antibody; Ovarian cancer associated antigen antibody; Ovarian tumor associated antigen antibody; Ovarian tumor associated antigen MOv18 antibody; Ovarian tumor-associated antigen MOv18 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human FOLR1 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.
  • 基因功能參考文獻：
    1. This study demonstrated a new approach using a combination of EpCAM and FRalpha as CTC-capture targets to increase the sensitivity of CTC detection in NSCLC efficiently, specifically, and quickly. PMID: 29352248
    2. Several experimental studies in mice and human epidemiological and genetics studies have suggested that FOLR1 abnormalities are involved in a portion of human neural tube defects (NTD), although the solo defect of FOLR1 did not cause NTD. (Review) PMID: 28244241
    3. that FOLR1 is highly expressed in ovarian cancer but is reduced following multidrug resistance. FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment PMID: 29433550
    4. mTORC1 or mTORC2 silencing markedly decreases the plasma membrane expression of FR-alpha and RFC transporter isoforms without affecting global protein expression PMID: 27562465
    5. High Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. PMID: 28410844
    6. The expression of folate receptor 1 (FOLR1) was significantly higher and occurred with higher frequency in metastatic lymph node samples from patients with advanced lung cancer. PMID: 29110850
    7. We identified eight novel variants in SLC19A1 and twelve novel variants in FOLR1, FOLR2, and FOLR3. Pathogenic variants include c.1265delG in SLC19A1 resulting in an early stop codon, four large insertion deletion variants in FOLR3, and a stop_gain variant in FOLR3 PMID: 28948692
    8. In this study, folate receptor alpha (FRa)-targeted nano-liposomes (FLP) were designed to enhance the anti-tumor effect by targeting delivery of exogenous PEDF gene to cervical cancer cells..These results clearly showed that FLP were desired carriers for PEDF gene and FLP/PEDF might represent a potential novel strategy for gene therapy of cervical cancer. PMID: 27576898
    9. Data show that higher folate receptor alpha (FRalpha) expression is predictive of a favorable prognosis in pancreatic ductal adenocarcinoma (PDAC) and FRalpha may represent a promising target for treatments. PMID: 28430580
    10. our results demonstrate the substantial therapeutic potential of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with dual targeting of PCFT and FRalpha toward Epithelial ovarian cancer that express a range of FRalpha, along with PCFT, as well as cisplatin resistance PMID: 28138029
    11. Low expression level of FOLR1 is associated with neuroendocrine lung tumors. PMID: 27064343
    12. FolR1 is a predictive candidate and a therapeutic target for medulloblastoma. PMID: 28416738
    13. Folr1 is a favorable target for fluorescence-guided surgery as tumor specific agent EC17 produced a clear fluorescent signal in ovarian and breast cancer tissue. PMID: 27014973
    14. The Folate receptor alpha is associated with the progression of cervical cancer and regulates cervical cancer cells growth through phosphorylating ERK1/2, c-Fos, and c-Jun, which are key factors of the ERK signaling pathway. PMID: 28782518
    15. Folate receptor alpha protein was expressed in the majority of lung adenocarcinomas and a minority of lung squamous cell carcinomas. Folate receptor alpha protein expression correlated with histologic grade for lung adenocarcinomas, and the greatest difference was observed between grade 1 and grade 3. PMID: 26599808
    16. The present study shows the efficacy of silencing HuR in lung cancer cells using folate-conjugated nanoparticle system that is directed towards folate receptor-alpha overexpressing cancer cells. PMID: 27328938
    17. This new protocol opens an effective way through synthesis and design of novel fluorescent nano-conjugates for FR expression investigation in tumor cells via targeted imaging, showing great potential in drug delivery mechanism study and cancer therapy PMID: 26606305
    18. Suppression of FOLR1 by RNA interference altered gene expression profile of taxol-resistant nasopharyngeal carcinoma cells. Apoptosis-related genes, gene alterations in viral carcinogenesis/MAPK pathways may be important for taxol resistance reversal. PMID: 26617855
    19. we confirmed the similarities between epithelial ovarian cancer and fallopian tube, normal and adenocarcinoma using FOLR1, FOLR2, CD68 and CD11b markers PMID: 25971554
    20. Suggest RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor-alpha. PMID: 26359629
    21. Folate receptor expression on murine and human adipose tissue macrophages PMID: 26149693
    22. Findings suggest the clinical development of IMGN853 as a novel targeted therapy for patients with folate receptor alpha (FRalpha)-expressing tumors. PMID: 25904506
    23. Suggest that FRalpha overexpression may play a role in the endometrioid endometrium carcinoma carcinogenesis and carcinoma progression from endometrial hyperplasia. PMID: 26191275
    24. triple negative/basal tumors were significantly associated with increased expression of FOLR1 mRNA, compared to ER+ and HER2+ tumors. PMID: 25816016
    25. Molecular dynamic simulation of the binding process of folic acid to folate receptor alpha PMID: 25323390
    26. Studies indicate folate receptor (FR) as a prognostic biomarker for ovarian cancer. PMID: 25564455
    27. The overexpression of folate receptor alpha mRNA was associated with growth of pituitary adenomas. PMID: 26014017
    28. this is the first study to simultaneously evaluate both DNA methylation and protein expression of all three folate transporter genes, FOLR1, PCFT, and RFC1, in colorectal cancer. PMID: 25697897
    29. FRalpha down-regulation might be capable of suppressing cervical cancer cell proliferation and promoting apoptosis. PMID: 25081683
    30. Survival times are improved in non-small-cell lung cancer patients whose tumors show strong membranous folate receptor alpha expression. PMID: 24993594
    31. the conditions associated with circulating FOLR1 protein in healthy individuals PMID: 24810481
    32. We concluded that quantitation of CTCs through FRalpha ligand-PCR could be a promising method for noninvasive diagnosis of bladder TCC. PMID: 24771263
    33. 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed folate receptor alpha (FRA). The expression of FRA was significantly associated with a worse disease-free survival. PMID: 24028341
    34. Expression of FOLR1 is higher in pituitary adenomas of patients who are older than 50 years. PMID: 23023342
    35. FOLR1 was significantly elevated in the serum of ovarian cancer patients compared to serum of both healthy controls and patients with benign gynecological conditions. PMID: 23528302
    36. The FRalpha gene was expressed in all parathyroid cells analyzed, and the FRbeta gene was expressed by most. PMID: 24206618
    37. crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution PMID: 23851396
    38. The data presented further support the hypothesis that folate receptor-alpha expression in gynecologic tumors is due to the cell of origin normally expressing this receptor PMID: 23518909
    39. EpCAM, FR-alpha, and VEGF-A are the most promising molecules for use in targeted intraoperative fluorescence imaging of endometriotic lesions owing to their favorable expression patterns and biomarker characteristics PMID: 23332132
    40. Studies indicate that folate receptor alpha (FOLR1), a folate transporter, is an attractive target for cancer therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. PMID: 23357463
    41. Overexpression of folate receptor alpha was associated with ovarian tumor progression. PMID: 23144806
    42. The folate receptor alpha translocates to the nucleus, where it binds to cis-regulatory elements at promoter regions of Fgfr4 and Hes1, and regulates their expression. PMID: 23243496
    43. a large percentage of lung cancers, including squamous cell carcinomas in addition to adenocarcinomas, strongly express folate receptor alpha PMID: 22984810
    44. PCR analysis had confirmed the existence of FR-alpha, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cells. PMID: 22304562
    45. High folate receptor alpha is associated with adenocarcinoma in non-small-cell lung carcinoma and and EGFR [corrected] mutation. PMID: 22729036
    46. alpha-FR can be a potential biomarker for the prediction of chemotherapeutic responses and clinical prognosis. PMID: 22265591
    47. studies suggest that different clinical severities do not necessarily correlate with residual function of folate receptor alpha mutants. PMID: 22586289
    48. FR-alpha was expressed in the majority of serous ovarian tumors, although >50% of cases showed only weak expression. PMID: 21647742
    49. FRalpha may play an important role in the development and progression of NFAs. PMID: 22089756
    50. An ancient double-mutated haplotype 1816delC-1841A in the FOLR1 gene, is demonstrated. PMID: 21938430

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Neurodegeneration due to cerebral folate transport deficiency (NCFTD)
  • 亞細(xì)胞定位：
    Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Cytoplasmic vesicle. Cytoplasmic vesicle, clathrin-coated vesicle. Endosome. Apical cell membrane. Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane.
  • 蛋白家族：
    Folate receptor family
  • 組織特異性：
    Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 3791

    OMIM: 136430

    KEGG: hsa:2348

    STRING: 9606.ENSP00000308137

    UniGene: Hs.73769



×
生命科學(xué)計算平臺